Recently, we found that glibenclamide could ameliorate the progression of atherosclerosis and reduce the production of inflammatory cytokines as well as the phosphorylation of p65 and ERK1/2 in Raw 264.7 macrophages [5]. Here, MAPK3 is linked to atherosclerosis.